Pharma News

LUM GmbH has recently entered into a strategic partnership with Alpharmaca Inc., a Shanghai-based company, to meet the increasing demand from the pharmaceutical and semiconductor sectors.

A groundbreaking study conducted in Brazil involving 728 infants under one year old has uncovered alarming effects of ultra-processed food consumption on gut microbiome diversity and abundance.

Kaisei Bio (688065) announced its 2024 annual performance report, showcasing remarkable financial growth. The company achieved revenues of 295.65 million yuan, reflecting a 39.84% increase compared to the previous year.

Supreme People's Court in China commenced hearings on a highly publicized patent dispute involving Boehringer Ingelheim, the German pharmaceutical giant, which is suing the National Intellectual Property Administration (NIPA).

In a startling trend, 48 pharmaceutical companies have announced workforce reductions within the first two months of 2025. This marks a significant increase compared to previous years, highlighting the growing challenges within the industry.

On March 3, 2025, AbbVie and Gubra announced a significant licensing agreement to collaboratively develop GUB014295, a promising long-acting amylin analogue aimed at treating obesity.

Novartis announced significant leadership appointments within its China operations. Li Yao, President of Novartis China, revealed that Tian Yu, the current head of Immunotherapy at Novartis China, will be promoted to President of Novartis Poland.

Gilead Sciences has set aside $200 million to potentially resolve an ongoing investigation into its promotional speakers program related to HIV drugs.

Glenmark Pharmaceuticals has initiated a recall of approximately 1.5 million bottles of its ADHD medication in the U.S., following findings of safety violations.

Pfizer CEO Albert Bourla announced that the pharmaceutical giant may shift its overseas manufacturing back to the United States in response to potential 25 percent tariffs on imported drugs.

AstraZeneca Pharma India Ltd has received crucial approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute its cancer treatment medication, Durvalumab.

The Therapeutic Goods Administration (TGA) has approved Dr. Reddy’s generic brands, Midostaurin Dr.Reddy’s and Midostaurin-RZ, which are indicated for the same conditions as Rydapt.

The Indian pharmaceutical industry is sounding the alarm over potential US tariffs on pharmaceutical exports, warning that such measures could lead to higher drug prices and possible shortages for American consumers.

In a strategic pivot towards the healthcare sector, ByteDance has made headlines by committing over 700 million yuan to enhance its presence in cell therapy and hospital construction.

The Indian pharmaceutical industry is making significant strides on the global stage, having overtaken U.S. counterparts with 752 FDA-registered manufacturing sites.

Glenmark Pharmaceuticals has officially launched its generic version of Epinephrine injection in the United States, a significant move that positions the company to capitalize on a market valued at approximately $42.7 million.

India's contract drug manufacturers are calling for urgent government assistance to overcome regulatory challenges and enhance their competitiveness against China.

AstraZeneca announced positive mid-term results from the Phase III SERENA-6 trial for its oral selective estrogen receptor degrader (SERD) camizestrant.

Eli Lilly has announced a significant investment of $2.7 billion aimed at establishing new manufacturing plants across the United States.

India is on the brink of becoming a prominent site for clinical trials, according to Sanjay Vyas, head of Parexel's India operations.